Experts have found that the drug abiraterone acetate can significantly improve the rate of survival in men with metastatic castration-resistant prostate cancer.
The results were presented to the American Society of Clinical Oncology last week. The drug recently received approval from the U.S. Food and Drug Administration, and results were even better than those that were originally reported in the New England Journal of Medicine last month.
"This trial establishes a new category of treatment for men who have progressed on conventional hormone therapies, as well as chemotherapy. It proves that these previously treated patients have tumors that are still hormonally responsive. Previously, this was the point in the illness where hormonal agents were typically not considered," Dr. Howard I. Scher, from Memorial Sloan-Kettering Cancer Center in New York City, said.
This breakthrough could mean incredible savings for those people trying to obtain a life insurance policy while suffering from this disease.The overall survival rate in the third trial was 15.8 months in the group that was receiving abiraterone, compared to an 11.2 month survival rate for the group that were not given the drug, according to the study.